Company intelligence / Profile preview

Urquima

Palau-solità i Plegamans, Catalonia, Spainnoucor.com ↗

Ownership: Private
Development stage: Other

Overview

Urquima manufactures and supplies commercial active pharmaceutical ingredients (APIs) for a variety of therapeutic areas, primarily as a contract development and manufacturing organization (CDMO). Clinical results are linked to partner drug products rather than independent clinical development by Urquima itself.

Therapeutic areas: ImmunologyEndocrinologyMen's HealthInfectious DiseasesPulmonologyCardiovascularNeurology
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Urquima.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urquima.